Key result
Oral 4-hydroxyisoleucine significantly improves glycemic control and lipid profiles in diabetic mice.
Answers are grounded in this paper and cite their sources.
The present report confirms the anti-hyperglycaemic and anti-dyslipidemic properties of 4-hydroxyisoleucine, an unusual amino acid isolated from Trigonella foenum-graecum seeds, for the first time in a well-characterised model of type II diabetes, i.e. db/db mice. 4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level. These results indicate that 4-hydroxyisoleucine exhibits significant potential as an anti-diabetic agent by suppressing progression of type II diabetic states that is suggested by enhancement of insulin sensitivity and glucose uptake in peripheral tissue.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2010) studied Type II diabetes (in C57BL/KsJ-db/db mice). 4-Hydroxyisoleucine was evaluated on Blood glucose, plasma insulin, triglycerides, total cholesterol, LDL-cholesterol, and HDL-cholesterol levels (p=< 0.05). Oral 4-hydroxyisoleucine (50 mg/kg) significantly reduced blood glucose, insulin, triglycerides, and LDL-C while raising HDL-C in db/db mice (p<0.05).
Synapse has enriched 5 related papers. Consider them for comparative context: